Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6)
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertension
Conditions
Hypertension, Hyperlipidemia
Trial Timeline
Nov 1, 2011 → May 1, 2012
NCT ID
NCT01609907About Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6)
Rosuvastatin+Valsartan (Sequence 1) + Rosuvastatin+Valsartan (Sequence 2) + Rosuvastatin+Valsartan (Sequence 3) + Rosuvastatin+Valsartan (Sequence 4) + Rosuvastatin+Valsartan (Sequence 5) + Rosuvastatin+Valsartan (Sequence 6) is a phase 1 stage product being developed by Yuhan for Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT01609907. Target conditions include Hypertension, Hyperlipidemia.
What happened to similar drugs?
20 of 20 similar drugs in Hypertension were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01609907 | Phase 1 | Completed |
Competing Products
20 competing products in Hypertension